A new method of analysing cancer patients’ blood for evidence of the disease could be up to ten times more sensitive than previous methods, according to new research from our Rosenfeld Group.
First authors Jonathan C. M. Wan and Katrin Heider discuss their latest paper "ctDNA monitoring using patient-specific sequencing
and integration of variant reads" published today (Wednesday 17 June 2020) in Science Translational Medicine.
Read more: [ Ссылка ]
